[go: up one dir, main page]

BRPI0721482A2 - Processo para preparação de um dissacarídeo de glicosamina com ligação b-(1-6) substituído assimetricamente ou simetricamente, processo, composto de fórmula 3, composto de fórmula 7, composto de fórmula 8, composto de fórmula 10a, composto de fórmula 11, composto de fórmula 11b, composto de fórmula 12b, composto de fórmula 12a, composto de fórmula 13, composto de fórmula 14, dissacarídeo 1,6-b sintético assimetricamente ou simetricamente substituído de fórmula 1, composto, composição, uso de um composto - Google Patents

Processo para preparação de um dissacarídeo de glicosamina com ligação b-(1-6) substituído assimetricamente ou simetricamente, processo, composto de fórmula 3, composto de fórmula 7, composto de fórmula 8, composto de fórmula 10a, composto de fórmula 11, composto de fórmula 11b, composto de fórmula 12b, composto de fórmula 12a, composto de fórmula 13, composto de fórmula 14, dissacarídeo 1,6-b sintético assimetricamente ou simetricamente substituído de fórmula 1, composto, composição, uso de um composto

Info

Publication number
BRPI0721482A2
BRPI0721482A2 BRPI0721482-0A BRPI0721482A BRPI0721482A2 BR PI0721482 A2 BRPI0721482 A2 BR PI0721482A2 BR PI0721482 A BRPI0721482 A BR PI0721482A BR PI0721482 A2 BRPI0721482 A2 BR PI0721482A2
Authority
BR
Brazil
Prior art keywords
compound
formula
asymmetrically
disaccharide
symmetrically substituted
Prior art date
Application number
BRPI0721482-0A
Other languages
English (en)
Inventor
Jacques Bauer
Carlo Chiavaroli
Stéphane Moutel
Original Assignee
Om Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma filed Critical Om Pharma
Publication of BRPI0721482A2 publication Critical patent/BRPI0721482A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0721482-0A 2006-11-16 2007-11-15 Processo para preparação de um dissacarídeo de glicosamina com ligação b-(1-6) substituído assimetricamente ou simetricamente, processo, composto de fórmula 3, composto de fórmula 7, composto de fórmula 8, composto de fórmula 10a, composto de fórmula 11, composto de fórmula 11b, composto de fórmula 12b, composto de fórmula 12a, composto de fórmula 13, composto de fórmula 14, dissacarídeo 1,6-b sintético assimetricamente ou simetricamente substituído de fórmula 1, composto, composição, uso de um composto BRPI0721482A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2006/003244 WO2008059307A2 (en) 2006-11-16 2006-11-16 Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
PCT/EP2007/062424 WO2008059035A2 (en) 2006-11-16 2007-11-15 Functionalized beta 1,6 glucosamine disaccharides and process for their preparation

Publications (1)

Publication Number Publication Date
BRPI0721482A2 true BRPI0721482A2 (pt) 2015-08-04

Family

ID=39093051

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0721482-0A BRPI0721482A2 (pt) 2006-11-16 2007-11-15 Processo para preparação de um dissacarídeo de glicosamina com ligação b-(1-6) substituído assimetricamente ou simetricamente, processo, composto de fórmula 3, composto de fórmula 7, composto de fórmula 8, composto de fórmula 10a, composto de fórmula 11, composto de fórmula 11b, composto de fórmula 12b, composto de fórmula 12a, composto de fórmula 13, composto de fórmula 14, dissacarídeo 1,6-b sintético assimetricamente ou simetricamente substituído de fórmula 1, composto, composição, uso de um composto

Country Status (15)

Country Link
US (2) US20100168054A1 (pt)
EP (1) EP2106403A2 (pt)
JP (1) JP2010510190A (pt)
KR (1) KR20090101162A (pt)
CN (1) CN101627048A (pt)
AR (1) AR063854A1 (pt)
AU (1) AU2007321172A1 (pt)
BR (1) BRPI0721482A2 (pt)
CA (1) CA2669401A1 (pt)
IL (1) IL198748A0 (pt)
MX (1) MX2009005054A (pt)
RU (1) RU2481352C2 (pt)
TW (1) TW200838546A (pt)
WO (2) WO2008059307A2 (pt)
ZA (1) ZA200903340B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
ES2773376T3 (es) * 2011-08-31 2020-07-10 Catabasis Pharmaceuticals Inc Amidas de ácidos grasos, composiciones y procedimientos de uso
US9241988B2 (en) 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
US9518078B2 (en) * 2012-04-12 2016-12-13 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
EP2844303B1 (en) * 2012-05-03 2021-09-15 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same
CN102977159A (zh) * 2012-11-18 2013-03-20 大连九信生物化工科技有限公司 一种苄醚保护d-氨基葡萄糖衍生物c3位上羟基的制备方法
WO2015035010A1 (en) * 2013-09-05 2015-03-12 Immune Design Corp. Vaccine compositions for drug addiction
CN105461767B (zh) * 2014-08-07 2019-03-12 富力 一种连翘苷的化学合成方法
US11013711B2 (en) 2016-06-10 2021-05-25 Beth Israel Deaconess Medical Center, Inc. Fatty acid esters of hydroxy fatty acids (FAHFAs) for use in the treatment of type 1 diabetes
CN106496987A (zh) * 2016-12-09 2017-03-15 南京林业大学 一种聚乳酸/纤维低聚糖共混物材料及其制备方法
WO2021050778A1 (en) * 2019-09-10 2021-03-18 The Penn State Research Foundation Lipopolysaccharide molecules for enhancing immune responses
CN111345426B (zh) * 2020-04-15 2023-06-30 中山市南方新元食品生物工程有限公司 一种食品保鲜剂
CN112175023A (zh) * 2020-10-31 2021-01-05 江南大学 一种脂肪醇乙酰壳二糖和脂肪醇n-乙酰葡糖胺的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504535B1 (fr) * 1981-04-28 1987-08-14 Choay Sa Disaccharides derives d'un acide uronique et d'une glucosamine et compositions pharmaceutiques les contenant pour le controle de la coagulation sanguine
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU700485B2 (en) * 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
JP2000226397A (ja) * 1998-11-30 2000-08-15 Otsuka Pharmaceut Factory Inc リピドａ中間体、その製法、リピドａ及びその誘導体の製法
JP2000297096A (ja) * 1999-02-10 2000-10-24 Sankyo Co Ltd エーテル型リピッドａ１位カルボン酸類縁体
HK1040519A1 (en) * 1999-02-10 2002-06-14 Sankyo Company, Limited Ether type lipid A1-carboxylic acid analog
JP2003514824A (ja) * 1999-11-15 2003-04-22 ビオミラ，インコーポレーテッド 合成脂質−ａ類似体およびその使用
WO2006095270A1 (en) * 2005-03-10 2006-09-14 Om Pharma Combination anticancer therapy or om-174 and pharmaceutical compositions therefor

Also Published As

Publication number Publication date
MX2009005054A (es) 2009-12-18
AU2007321172A1 (en) 2008-05-22
WO2008059035A3 (en) 2009-09-24
RU2481352C2 (ru) 2013-05-10
AR063854A1 (es) 2009-02-25
IL198748A0 (en) 2010-02-17
US20130035479A1 (en) 2013-02-07
CN101627048A (zh) 2010-01-13
TW200838546A (en) 2008-10-01
RU2009122714A (ru) 2010-12-27
KR20090101162A (ko) 2009-09-24
ZA200903340B (en) 2010-10-27
JP2010510190A (ja) 2010-04-02
CA2669401A1 (en) 2008-05-22
WO2008059307A2 (en) 2008-05-22
WO2008059035A2 (en) 2008-05-22
US20100168054A1 (en) 2010-07-01
EP2106403A2 (en) 2009-10-07

Similar Documents

Publication Publication Date Title
BRPI0721482A2 (pt) Processo para preparação de um dissacarídeo de glicosamina com ligação b-(1-6) substituído assimetricamente ou simetricamente, processo, composto de fórmula 3, composto de fórmula 7, composto de fórmula 8, composto de fórmula 10a, composto de fórmula 11, composto de fórmula 11b, composto de fórmula 12b, composto de fórmula 12a, composto de fórmula 13, composto de fórmula 14, dissacarídeo 1,6-b sintético assimetricamente ou simetricamente substituído de fórmula 1, composto, composição, uso de um composto
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
NO20082615L (no) Formaldehydfritt fenolharpiks-bindemiddel
BRPI0717695A2 (pt) "composição, uso de uma compsição e processo de preparação de uma composição"
BRPI0815324A2 (pt) "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
BRPI0411268A (pt) processo para a preparação de um composto 3-aril butil-amina substituìdo
BRPI0811712A2 (pt) "composto, processo de preparação de um composto e composição farmacéutica".
EP1948732A4 (en) PROCESS FOR PREPARING A BITUMINOUS BINDER COMPOSITION
BRPI0611956A2 (pt) composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
WO2007031548A3 (en) Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof
BRPI0908616A2 (pt) "composto, composição de fluido de perfuração, processo de preparação de um composto de poliamida e uso de um composto"
BRPI0905663A2 (pt) "emulsão estável, processo de preparação da emulsão estável e uso emulsão"
BRPI0606644A2 (pt) derivados de 4-carboxamida tiazola
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0815784A2 (pt) Processo para a preparação de 1,2-propanodiol
IL197294A0 (en) Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the ??2 adrenergic receptor
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
BRPI1006162A2 (pt) "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
DK2049079T3 (da) Sammensætninger, der indeholder kvaternære ammoniumforbindelser
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
EP2013196A4 (en) DISUBSTITUTED ANILINE COMPOUNDS
BRPI0922381A2 (pt) "processo para síntese de di-ou oligossacarídeos de l-fucose e novos derivados intermediários de 2,3,4-tribenzil-fucose dos mesmos."
BRPI0919918A2 (pt) Composto de vanilina e de etilvanilina, processo de preparação do mesmo, composição, e, aplicação do composto.
WO2007126900A3 (en) Antifungal agents
BR112012016201A2 (pt) ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.